We have an ongoing scientific programme to explore how Apomorphine Hydrochloride can be offered to the most appropriate people with Parkinson’s via the least invasive or intrusive means. We are also evaluating market opportunities within the field of neurology and continuously exploring new ways to bring products to market.
We include the generation of clinical trial evidence to help health care professionals, and those who fund healthcare, select those people with Parkinson’s who may receive the most benefit from apomorphine therapy. To aid research we also support the generation of new rating scales that offer improved measurement of aspects reported to be important for the quality of life of people with Parkinson’s.
In addition we have several reformulation projects which are exploring alternative modes of administration that could offer improvements. Our goals are ease of use and tolerability, both making the benefit of apomorphine more accessible to people with Parkinson’s. For either our continuous or intermittent delivery devices our goal is to develop and offer a range of options that offer innovative features combined with ease of use that can be matched to a patient’s needs.
Clinical Trials – for more information please visit https://clinicaltrials.gov/ct2/show/NCT02006121?term=toledo&rank=8
To view the TOLEDO protocol, please visit https://www.volkslaboratory.pro/wp-content/uploads/2018/11/TOLEDO-Protocol-Final-clean-3-0-20140702.pdf
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson’s Disease (TOLEDO)
The TOLEDO study data will be available to investigators whose proposed use of the data has been approved by an independent review committee. Individual participant data that underlie the results reported in this article will be shared (text, tables, figures, and appendices), after de-identification, along with the study protocol, statistical analysis plan and analytic code. These data will be available 3 months following the article’s publication and will be available for 36 months from publication. Requests and proposals should be directed to CTD@britannia-biopharm.co.uk